Fourier Rehab is revolutionizing rehabilitation technology, making it easier for patients to recover from mobility issues and brain-related conditions. Established initially as Fourier Intelligence in 2015, the company underwent a strategic rebranding to Fourier and Fourier Rehab in 2024. The company is now focusing on two main areas: Rehabilitation Robotics and Embodied AI. This has helped Fourier Rehab become a world leader in both rehabilitation robots and humanoid robots. Their main office is located in Shanghai, and they have approximately 500 team members worldwide.
Interview with Owen Teoh, Managing Director at Fourier Rehab International Division.
A brief description of the company and its activities.
Owen Teoh: Our core mission is to develop robotic systems that bridge the crucial gap between advanced technology and practical clinical applications. Unlike conventional rehabilitation methods that rely heavily on manual therapy techniques, our solutions integrate cutting-edge artificial intelligence, advanced biomechanics analysis, and precision robotics to deliver personalized, data-driven rehabilitation experiences.
The company’s technological portfolio includes humanoid robots, lower limb exoskeletons, and comprehensive rehabilitation robotics, catering to diverse healthcare markets. Our GRx series humanoid robot platforms illustrate this integration, featuring advanced sensor systems capable of real-time environmental mapping, autonomous navigation, and adaptive patient interaction. While still in development, these capabilities will allow the robot to serve as both a therapeutic tool and a clinical assistant in the future, delivering consistent and precise therapy interventions while generating valuable patient progress data.
Fourier Rehab’s approach goes beyond developing individual devices to create comprehensive rehabilitation ecosystems. We work closely with rehabilitation centers, hospitals, research institutions, and clinical professionals to ensure our solutions tackle real-world healthcare challenges while adhering to strict medical device standards and regulatory requirements.
What are the main areas of activity of the company?
O.T: Fourier Rehab is transforming physical rehabilitation by making advanced robotic therapy accessible worldwide, helping patients in recovering from neurological and musculoskeletal conditions more effectively than ever before.
Our main areas of activity center around five core pillars:
- Robotic Rehabilitation Technology Development
We design and manufacture advanced robotic rehabilitation devices specifically for patients recovering from strokes, spinal cord injuries, cerebral palsy, and other neurological conditions. Our hardware solutions are engineered to deliver precise, repeatable therapy that adapts to each patient’s unique needs and capabilities.
- AI-Powered Clinical Solutions
Beyond the hardware, we integrate artificial intelligence and real-time data analytics into our systems to enhance their capabilities. This technology enables therapists to deliver truly personalized treatment programs, track patient progress with unparalleled accuracy, and make data-driven adjustments to improve clinical outcomes.
- Clinical Implementation & Training
We collaborate closely with rehabilitation centers and hospitals globally, not only to implement our devices but also to ensure that medical professionals are thoroughly trained and confident in using them. This comprehensive support approach includes ongoing technical assistance, clinical protocol development, and hands-on training programs that maximize the therapeutic value of our technology.
- Research & Development Partnerships
We maintain strategic collaborations with leading hospitals, universities, and research institutions worldwide to validate and improve our technologies continually. Our research partners include top-tier rehabilitation institutions such as Shirley Ryan AbilityLab in Chicago, the KITE Research Institute at the Toronto Rehabilitation Institute – University Health Network, ETH Zürich in Switzerland, National Healthcare Group in Singapore, and the University of Melbourne. These partnerships ensure our solutions remain at the forefront of rehabilitation science.
- Market Development & Education
Education and advocacy are fundamental to our mission. We actively train clinicians and raise awareness through industrial visits by universities and educational institutions about the benefits of robotic and AI-assisted rehabilitation. By demonstrating the clinical and economic advantages of our technology, we’re helping drive broader adoption and ultimately deliver better outcomes for patients globally.
Through these integrated activities, Fourier Rehab is not just developing rehabilitation technology; we’re building an ecosystem that transforms how physical therapy is delivered, making advanced care accessible to patients worldwide while supporting clinicians with the tools and knowledge they need to achieve exceptional results.
What’s the news about new products/services?
O.T: At Fourier Rehab, our focus has always been on developing meaningful and intelligent solutions that enable clinicians to accelerate patient recovery. Over the past year, we have launched several new products that reflect our commitment to more innovative, data-driven rehabilitation. We are already witnessing their impact in clinical practice worldwide.
One of our most exciting innovations is the MetaMotus™ Galileo. This state-of-the-art platform combines biomechanics, rehabilitation, and sports science to provide an immersive, safe, and effective environment for recovery, designed to enhance outcomes and reduce rehabilitation timelines. It was developed in close collaboration with therapists to meet a growing need for objective assessment tools that can also guide real-time therapy. The system enables clinicians to assess movement, such as gait or posture, using embedded sensors and motion tracking, and then immediately initiate therapy based on that data. What makes it especially powerful is how it adapts to each patient’s progress during a session, offering a more personalized and measurable approach to treatment.
In parallel, our flagship device – the ArmMotus™ EMU has continued to expand its presence as a leading solution for upper-limb rehabilitation. This robotic system provides gravity-compensated, multi-directional movement training with haptic feedback, enabling high-repetition therapy that is both challenging and safe. One of its most impactful features is the ability to conduct group therapy sessions while maintaining individualized settings and performance tracking, allowing therapists to achieve more with less while improving patient throughput. Clinicians value the intuitive nature of its use, and it has been recognized globally for both design and clinical functionality, winning multiple awards, including the IERA Awards 2023, Red Dot Winner 2022, iF Design Awards 2022, Medical Design Award, and Good Design Award 2022.
We are also witnessing strong adoption of the ExoMotus™ M4, one of Fourier Rehab’s flagship devices. It is a lower-limb exoskeleton designed for gait training. The ExoMotus™ M4 supports a variety of therapy modes, from passive to assistive, adapting to each patient’s capabilities in real-time. It is utilized with patients recovering from strokes, spinal cord injuries, multiple sclerosis, and other neuromotor conditions, and is proving especially effective in helping restore balance, coordination, and walking confidence. Because it enables patients to move naturally in a real-world environment, it serves as an invaluable tool for fostering functional independence early in the rehabilitation journey.
Together, these solutions reflect our broader vision: to transform rehabilitation into a more precise, efficient, and engaging experience. We are not just building devices; we are creating intelligent platforms that integrate seamlessly into clinical workflows, deliver measurable results, and ultimately raise the standard of care. As we continue to grow, we remain focused on enabling therapists and patients, shaping a future where advanced rehabilitation is accessible to all.
What are the ranges of products/services?
O.T: At the heart of Fourier Rehab’s ecosystem is the RehabHub™ – a fully integrated, modular rehabilitation platform designed to transform how therapy is delivered across clinical and community settings. The RehabHub™ functions not as a single device or tool, but as a comprehensive solution that merges robotics, biomechanics, digital infrastructure, and evidence-based therapy into a unified and intelligent system. It provides the foundation for building adaptable, efficient, and patient-centered rehabilitation environments.
The RehabHub™ is structured to support the entire continuum of care. Whether implemented in a hospital, outpatient facility, or community-based clinic, it ensures that patients receive consistent, data-driven therapy throughout every phase of recovery.
At the core of this system is the InfinityNet™ – a secure, cloud-connected data network that synchronizes and supports all components within the RehabHub™. It enables seamless data integration, allowing clinicians to access real-time performance metrics, track long-term patient progress, and adjust therapy plans remotely or on-site. This connectivity ensures continuity of care across settings and promotes personalized treatment by transforming therapy data into actionable insights.
Through our InfinityNet™, the RehabHub™ can foster a responsive rehabilitation experience that adapts to each patient’s evolving needs. Harmonizing data, devices, and therapy protocols into a single digital framework allows therapists to deliver more effective, measurable, and scalable rehabilitation.
Lastly, Fourier Rehab also offers EXOPS™, our Exoskeleton & Robotics Open Platform System. EXOPS™ is an open-source development framework designed to accelerate innovation by allowing researchers and developers to build applications on top of our existing exoskeleton and robotics hardware. This promotes faster and more meaningful adoption of wearable robots in real-world settings, fostering collaboration between academia and industry.
What is the state of the market where you are currently active?
O.T: The rehabilitation robotics market is experiencing remarkable growth and deepening clinical integration worldwide. As of 2025, the market is valued at approximately USD 496 million. This figure highlights the rapid expansion we’ve witnessed, driven by the increasing demand for robotic-assisted rehabilitation tools across healthcare environments.
Looking ahead, the market is projected to continue growing vigorously, with its value expected to reach approximately USD 1.78 billion by 2034, reflecting a strong compound annual growth rate of around 15.2%. These projections align closely with our internal estimates, confirming that the momentum in rehabilitation robotics is both robust and sustained.
From a clinical perspective, these numbers represent a paradigm shift. Robotic rehabilitation has moved beyond niche experimentation—it’s now embedded in standard care protocols across rehabilitation hospitals, outpatient centers, and community clinics. This shift is driven by growing scientific evidence showing that robotic systems enhance patient outcomes, improve therapy efficacy, and improve operational efficiency through repeated, data-rich training.
Geographically, North America remains the dominant market, supported by a robust infrastructure and a favorable reimbursement framework. However, the Asia‑Pacific region is emerging as a high-growth arena, fueled by increasing healthcare investment, aging demographics, and proactive government policies. Europe continues to advance with focused research and widespread deployment of exoskeletons, while Latin America and the Middle East are emerging as promising future markets.
In summary, we are operating in a market marked by significant expansion, a shift toward clinical mainstreaming, and broad international adoption, creating an ideal ecosystem in which Fourier Rehab can deliver scalable, data-driven solutions that genuinely capture the trajectory of rehabilitation innovation.
Source: globenewswire.com+4globenewswire.com+4globenewswire.com+4
What can you tell us about market trends?
O.T: The rehabilitation robotics sector is witnessing dynamic and transformative market trends that indicate a new era for patient recovery and therapy delivery. One of the most significant trends is the rapid clinical adoption of robotic rehabilitation solutions. What was once seen as emerging or experimental technology is now being incorporated into routine care, particularly for neurological, musculoskeletal, and post-surgical recovery. This shift is mainly driven by the demand for more efficient, scalable, and outcomes-focused care models, especially in response to aging populations and clinician shortages.
Another significant trend is the growing personalization and integration of data in therapy. Modern robotic systems are equipped with advanced sensors and software that facilitate real-time monitoring, adaptive feedback, and progress tracking. This data-centric approach enables therapists to provide more tailored and precise interventions, enhancing both patient engagement and clinical outcomes.
We are also observing strong momentum in tele-rehabilitation and hybrid care models, where robotic solutions are utilized in both inpatient and outpatient settings, and in some cases, even in patients’ homes. This reflects a broader trend in healthcare toward decentralization and enhanced accessibility, particularly in light of the lessons learned from the COVID-19 pandemic.
From a business perspective, global investment and public sector support are accelerating, especially in high-growth regions like the Asia-Pacific. Governments are actively promoting the adoption of assistive technologies, which is further strengthened by increasing private sector investment in medical technology (MedTech), startups, and research and development (R&D). This has made the rehabilitation robotics market one of the fastest-growing segments in the healthcare technology industry.
Lastly, regulatory clarity is improving, with more defined pathways for the approval, reimbursement, and clinical integration of robotic rehabilitation devices. This helps innovators bring products to market faster while ensuring that safety and efficacy standards are met.
In summary, market trends indicate a future where robotic rehabilitation is not just complementary, but central to delivering high-quality, patient-centered care on a large scale. At Fourier Rehab, we are both responding to and helping shape these trends through continuous innovation and global partnerships.
What are the most innovative products/services marketed?
O.T: Among the wide range of products developed by Fourier Rehab, the MetaMotus™ Galileo is the most advanced and comprehensive rehabilitation platform, expertly designed to bridge biomechanical analysis, virtual reality, and robotic assistance. Developed through close collaboration with clinicians and researchers, Galileo merges a six-degree-of-freedom motion platform, dual‑belt treadmill, force plate, motion capture, and immersive VR – all orchestrated via our Galileo X software suite.
This system empowers therapists first to assess functional challenges, such as balance, gait, posture, and motor control, and then seamlessly transition into targeted, adaptive therapy within a simulated real-world environment. Clinicians can, for example, replicate activities of daily living or sports scenarios while the Galileo dynamically adjusts support and records precise movement data.
It also supports a wide range of rehabilitation applications, facilitating bilateral upper-limb training by integrating two ArmMotus™ EMUs for mirrored movement patterns, such as rowing or swimming. For gait rehabilitation, it combines a treadmill, force plates, and exoskeleton integration (e.g., with ExoMotus™ M4) to deliver safe and effective early-stage sit-to-stand and ambulation training. The VR-enhanced environment enables immersive training in balance, motor skills, and even psychological therapy, ranging from fall prevention to exposure therapy for PTSD.
The platform also supports research and development use cases: its open architecture assists with developing and testing robotics, wearables, and assessment protocols. The MetaMotus™ Galileo has earned recognition through prestigious design awards, including the Good Design Award and Shanghai International Design 100+, a testament to its innovative and user-centric design.
It has been implemented in leading centers, such as Shuguang Hospital, the Sunshine Rehabilitation Center in Shanghai, and the PERKESO Rehabilitation Centre in Malaysia, validating its effectiveness in real-world clinical settings.
In essence, the MetaMotus™ Galileo is a flagship exemplar of Rehabilitation 4.0. It combines rigorous biomechanics assessment with adaptive therapy, immerses patients in realistic environments, and delivers data-driven insights, helping clinicians deliver smarter, more effective rehabilitation.
What estimations do you have for the second half of 2025?
O.T: For the second half of 2025, we anticipate continued momentum in the rehabilitation technology sector, driven by increasing institutional investment in more innovative, data-informed care models. Demand is expected to grow steadily across both hospital-based and outpatient rehabilitation settings, as providers seek solutions that improve efficiency, support clinical decision-making, and address therapist shortages.
Strategically, we foresee more healthcare systems taking steps to integrate rehabilitation more deeply into their long-term care pathways, with technology playing a central role in standardizing care delivery, enhancing patient engagement, and improving measurable outcomes.
We also expect a greater emphasis on connectivity and interoperability, as healthcare providers increasingly seek platforms that consolidate data, integrate with electronic health records, and support long-term patient tracking across multiple care sites. As a result, we’re focusing on helping our partners create unified, flexible rehabilitation environments that can scale with clinical demand.
Globally, we’re observing strong engagement from markets in Asia, the Middle East, and Europe, where health infrastructure development and policy support for rehabilitation are creating meaningful opportunities for innovation and collaboration.
As always, our approach for the remainder of 2025 remains grounded in listening to clinicians, supporting the implementation of successful solutions, and adapting to regional healthcare priorities while continuing to drive the evolution of rehabilitation practice.